A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

NCT05141786 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small- Cell Lung Cancer (NSCLC)

Interventions

DRUG: MRG002

Sponsor

Shanghai Miracogen Inc.